{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T16:16:14Z","timestamp":1726503374422},"reference-count":153,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1016\/j.pharmthera.2005.05.006","type":"journal-article","created":{"date-parts":[[2005,8,31]],"date-time":"2005-08-31T07:09:05Z","timestamp":1125472145000},"page":"334-352","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacological treatment of ischemic stroke"],"prefix":"10.1016","volume":"108","author":[{"given":"Paul","family":"Bentley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pharmthera.2005.05.006_bib1","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/01.STR.0000157668.39374.56","article-title":"Emergency administration of abciximab for treatment of patients with acute ischemic stroke. Results of a randomized phase 2 trial","volume":"36","author":"AbESTT","year":"2005","journal-title":"Stroke"},{"issue":"16","key":"10.1016\/j.pharmthera.2005.05.006_bib2","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.279.16.1265","article-title":"Document types: feature low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators","volume":"279","author":"Adams","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib3","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.STR.0000064841.47697.22","article-title":"Guidelines for the early management of patients with ischemic stroke","volume":"34","author":"Adams","year":"2003","journal-title":"Stroke"},{"issue":"21","key":"10.1016\/j.pharmthera.2005.05.006_bib4","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1056\/NEJMoa041175","article-title":"Ultrasound-enhanced thrombolysis for acute ischemic stroke","volume":"351","author":"Alexandrov","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/jnnp.60.2.197","article-title":"Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia","volume":"60","author":"Algra","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib6","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1161\/01.STR.32.4.980","article-title":"Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice","volume":"32","author":"Amin-Hanjani","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","author":"Antiplatelet Trialists' Collaboration","year":"1994","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.pharmthera.2005.05.006_bib8","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/01.STR.0000091233.04524.0C","article-title":"Effect of blood pressure during the acute period of ischemic stroke on stroke outcome: a tertiary analysis of the GAIN International Trial","volume":"34","author":"Aslanyan","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib9","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1161\/01.STR.12.6.723","article-title":"Thresholds in cerebral ischemia\u2014the ischemic penumbra","volume":"12","author":"Astrup","year":"1981","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.pharmthera.2005.05.006_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000039","article-title":"Interventions for deliberately altering blood pressure in acute stroke","author":"BASC (Blood pressure in Acute Stroke Collaboration)","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib11","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0140-6736(01)05837-8","article-title":"Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin controlled trial","volume":"358","author":"Bath","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib12","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200006153422402","article-title":"Thrombotic thrombocytopenic purpura associated with clopidogrel","volume":"342","author":"Bennett","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib13","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(00)02085-7","article-title":"Low molecular weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomized study. HAEST Study Group Heparin in Acute Embolic Stroke Trial","volume":"355","author":"Berge","year":"2000","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.pharmthera.2005.05.006_bib14","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/01.PHM.0000083668.48396.84","article-title":"Beneficial effect of donepezil on sensorimotor function after stroke","volume":"82","author":"Berthier","year":"2003","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib15","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/01.STR.27.5.875","article-title":"Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome","volume":"27","author":"Brandt","year":"1996","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.pharmthera.2005.05.006_bib16","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.neuropharm.2004.03.003","article-title":"Sodium channel blocking activity of AM-36 and sipatrigine (BW619C89): in vitro and in vivo evidence","volume":"47","author":"Callaway","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib17","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0140-6736(05)17742-3","article-title":"Homocysteine and stroke: evidence on a causal link from Mendelian randomization","volume":"365","author":"Casas","year":"2005","journal-title":"Lancet"},{"issue":"9066","key":"10.1016\/j.pharmthera.2005.05.006_bib19","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(97)04010-5","article-title":"Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group","volume":"349","author":"CAST","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib20","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1161\/01.STR.14.5.668","article-title":"Immediate anticoagulation of embolic stroke: a randomized trial","volume":"14","author":"CESG: Cerebral Embolism Study Group","year":"1983","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.pharmthera.2005.05.006_bib21","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/archneur.56.9.1098","article-title":"Heparin in acute stroke with atrial fibrillation: clinical relevance of very early treatment","volume":"56","author":"Chamorro","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa042087","article-title":"Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding","volume":"352","author":"Chan","year":"2004","journal-title":"N Engl J Med"},{"issue":"243","key":"10.1016\/j.pharmthera.2005.05.006_bib23","article-title":"Indications for early aspirin use in acute ischaemic stroke: a combined analysis of over 40,000 randomised patients","volume":"30","author":"Chen","year":"1999","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib24","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.10555","article-title":"Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke","volume":"53","author":"Chen","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib25","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1212\/WNL.45.8.1488","article-title":"The warfarin-aspirin symptomatic intracranial disease study","volume":"45","author":"Chimowitz","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib26","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa043033","article-title":"For the warfarin-aspirin symptomatic intracranial disease trial investigators","volume":"352","author":"Chimowitz","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib28","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1161\/01.STR.31.8.1812","article-title":"Timing of recanalization after tissue plasminogen activator therapy determined by transcranial Doppler correlates with clinical recovery from ischemic stroke","volume":"31","author":"Christou","year":"2000","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib29","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1001\/jama.282.21.2019","article-title":"Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke","volume":"282","author":"Clark","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib30","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1161\/01.STR.31.4.811","article-title":"The rtPA (alteplase) 0- to 6-hour acute stroke trial: Part A (A0276g). Results of a double blind, placebo-controlled, multicenter study. Thrombolytic Therapy in Acute Ischemic Stroke Study Investigators","volume":"31","author":"Clark","year":"2000","journal-title":"Stroke"},{"issue":"9311","key":"10.1016\/j.pharmthera.2005.05.006_bib32","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib33","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/01.STR.30.3.484","article-title":"Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis","volume":"30","author":"de Bruijn","year":"1999","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib34","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ana.410320113","article-title":"Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke","volume":"32","author":"del Zoppo","year":"1992","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib35","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/01.STR.29.1.4","article-title":"PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke","volume":"29","author":"del Zoppo","year":"1998","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.pharmthera.2005.05.006_bib36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11883-004-0061-2","article-title":"Small molecule activators of the heat shock response and neuroprotection from stroke","volume":"6","author":"DeFranco","year":"2004","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"10.1016\/j.pharmthera.2005.05.006_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.neulet.2004.01.034","article-title":"Effect of diets with different magnesium content in ischemic stroke rats","volume":"362","author":"Demougeot","year":"2004","journal-title":"Neurosci Lett"},{"issue":"6","key":"10.1016\/j.pharmthera.2005.05.006_bib38","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1161\/01.STR.24.6.796","article-title":"Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project","volume":"24","author":"Dennis","year":"1993","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib39","first-page":"685","article-title":"Outcome of stroke patients without angiographic arterial occlusion","volume":"21","author":"Derex","year":"2001","journal-title":"AJNR"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib40","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/bmj.321.7270.1183","article-title":"Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis","volume":"321","author":"Derry","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","article-title":"European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke","volume":"143","author":"Diener","year":"1996","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib42","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1161\/01.STR.32.1.22","article-title":"Treatment of acute ischemic stroke with the low-molecular weight heparin certoparin: results of the TOPAS trial. Therapy of Patients With Acute Stroke (TOPAS) Investigators","volume":"32","author":"Diener","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib44","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jama.276.12.961","article-title":"Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group","volume":"276","author":"Donnan","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib45","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ana.10612","article-title":"Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction","volume":"54","author":"Dore","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib46","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0140-6736(93)92358-Z","article-title":"Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke","volume":"342","author":"EAFT (European Atrial Fibrillation Trial) Study Group","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib47","first-page":"467","article-title":"Dynamic cerebral autoregulation and beat to beat blood pressure control are impaired in acute ischaemic stroke","volume":"72","author":"Eames","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib48","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(98)03454-0","article-title":"Blood pressure, cholesterol, and stroke in eastern Asia","volume":"352","author":"Eastern Stroke and Coronary Heart Disease Collaborative Research Group","year":"1998","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.pharmthera.2005.05.006_bib49","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/BF03402029","article-title":"Erythropoietin therapy for acute stroke is both safe and beneficial","volume":"8","author":"Ehrenreich","year":"2002","journal-title":"Mol Med"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib50","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/0140-6736(91)90607-Q","article-title":"Heparin treatment in sinus venous thrombosis","volume":"338","author":"Einhaupl","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib51","doi-asserted-by":"crossref","first-page":"8880","DOI":"10.1073\/pnas.95.15.8880","article-title":"Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase","volume":"95","author":"Endres","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib52","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1161\/hs1201.099520","article-title":"Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation?","volume":"32","author":"Evans","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib53","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0735-1097(99)00003-0","article-title":"Atherosclerosis of the thoracic aorta and aortic debris as a marker of poor prognosis: benefit of oral anticoagulants","volume":"33","author":"Ferrari","year":"1999","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.pharmthera.2005.05.006_bib54","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/01.STR.0000114203.75678.88","article-title":"Stroke MRI is accurate in hyperacute intracerebral hemorrhage. A multicentre study on the validity of stroke imaging","volume":"35","author":"Fiebach","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib55","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0022-510X(89)90060-9","article-title":"Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours","volume":"91","author":"Fieschi","year":"1989","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.pharmthera.2005.05.006_bib56","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bbrc.2003.09.171","article-title":"Platelet factor 4 neutralizes heparan sulfate-enhanced antithrombin inactivation of factor Xa by preventing interaction(s) of enzyme with polysaccharide","volume":"311","author":"Fiore","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib57","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJMp048288","article-title":"Coxibs and cardiovascular disease","volume":"351","author":"Fitzgerald","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib58","first-page":"186","article-title":"Local intraarterial fibrinolysis in vertebrobasilar thrombosis\u2014prognostic criteria","volume":"6","author":"Fox","year":"1996","journal-title":"Abstr Cerebrovasc Dis"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib59","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.282.21.2003","article-title":"Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomised controlled trial. Prolyse in acute cerebral thrombolembolism","volume":"282","author":"Furlan","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib60","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jns.2004.01.015","article-title":"Effect of pre-treatment with statins on the severity of acute ischemic cerebrovascular events","volume":"221","author":"Greisenegger","year":"2004","journal-title":"J Neurol Sci"},{"issue":"5 Suppl.","key":"10.1016\/j.pharmthera.2005.05.006_bib61","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.1097\/01.CCM.0000126127.87484.2B","article-title":"Activated protein C and ischemic stroke","volume":"32","author":"Griffin","year":"2004","journal-title":"Crit Care Med"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib62","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archneur.55.4.466","article-title":"Early intravenous thrombolysis with recombinant tissue-type plasminogen activator in vertebrobasilar ischemic stroke","volume":"55","author":"Grond","year":"1998","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib63","series-title":"The cochrane library, Issue 1","article-title":"Anticoagulants for acute ischaemic stroke (Cochrane Review)","author":"Gubitz","year":"2004"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib64","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1161\/01.STR.19.10.1216","article-title":"Intraarterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease","volume":"19","author":"Hacke","year":"1988","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib65","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1001\/jama.274.13.1017","article-title":"Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke (ECASS I)","volume":"274","author":"Hacke","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib66","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(98)08020-9","article-title":"Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)","volume":"352","author":"Hacke","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib67","first-page":"S3","article-title":"Thrombolysis in acute ischemic stroke: controlled trials and clinical experience","volume":"53","author":"Hacke","year":"1999","journal-title":"Neurology"},{"issue":"9411","key":"10.1016\/j.pharmthera.2005.05.006_bib68","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(04)15692-4","article-title":"Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials","volume":"363","author":"Hacke","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib69","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S0140-6736(99)04407-4","article-title":"Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations","volume":"354","author":"Hankey","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib70","series-title":"The cochrane library","article-title":"Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin in the secondary prevention of stroke and other important vascular events among high risk patients (protocol for a Cochrane Review)","author":"Hankey","year":"1999"},{"issue":"1","key":"10.1016\/j.pharmthera.2005.05.006_bib71","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1227\/01.NEU.0000097556.08044.1F","article-title":"Bivalirudin for endovascular intervention in acute ischemic stroke: case report","volume":"54","author":"Harrigan","year":"2004","journal-title":"Neurosurgery"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib72","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(04)15690-0","article-title":"Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions","volume":"363","author":"Heart Protection Study Collaborative Group","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib73","first-page":"19","article-title":"FISS bis Investigators Group: fraxiparine in ischaemic stroke study","volume":"8","author":"Hommel","year":"1998","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib74","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0140-6736(95)91179-0","article-title":"Termination of trial of streptokinase in severe acute ischaemic stroke","volume":"345","author":"Hommel","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib75","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"HOPE: The Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib76","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(97)04011-7","article-title":"The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both or neither among 19,435 patients with acute ischemic stroke","volume":"349","author":"International Stroke Trial Collaborative Group","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib77","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0140-6736(04)15490-1","article-title":"Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke Trial): randomized controlled trial","volume":"363","author":"Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib78","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","volume":"2 (8607)","author":"ISIS-2","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib79","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(99)01146-0","article-title":"Early recanalization in acute ischemic stroke saves tissue at risk defined by MRI","volume":"353","author":"Jansen","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib80","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1001\/archinte.159.11.1248","article-title":"A metaregression analysis of the dose\u2013response effect of aspirin on stroke","volume":"159","author":"Johnson","year":"1999","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.pharmthera.2005.05.006_bib81","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/01.WCB.0000100062.36077.84","article-title":"Intracerebral hirudin injection attenuates ischemic damage and neurologic deficits without altering local cerebral blood flow","volume":"24","author":"Karabiyikoglu","year":"2004","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib82","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jama.283.9.1151","article-title":"Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience","volume":"283","author":"Katzan","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib83","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1001\/archneur.61.3.346","article-title":"Utilization of intravenous tissue plasminogen activator for acute ischemic stroke","volume":"61","author":"Katzan","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib84","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1056\/NEJM199512143332402","article-title":"Low-molecular-weight heparin for the treatment of acute ischemic stroke","volume":"333","author":"Kay","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib85","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1056\/NEJMe058022","article-title":"Warfarin, aspirin, and intracranial vascular disease","volume":"352","author":"Koroshetz","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib86","series-title":"The cochrane library","article-title":"Secondary prevention following stroke or TIA in patients with nonrheumatic atrial fibrillation: anticoagulant therapy versus control (Cochrane review)","author":"Koudstaal","year":"1999"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib87","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/01.CIR.97.12.1129","article-title":"Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors","volume":"97","author":"Laufs","year":"1998","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.pharmthera.2005.05.006_bib88","first-page":"1470","article-title":"Sequential combination of intravenous recombinant tissue plasminogen activator and intra-arterial urokinase in acute ischemic stroke","volume":"25","author":"Lee","year":"2004","journal-title":"Am J Neuroradiol"},{"issue":"5681","key":"10.1016\/j.pharmthera.2005.05.006_bib89","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1126\/science.1098313","article-title":"Derivatives of erythropoietin that are tissue protective but not erythropoietic","volume":"305","author":"Leist","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib90","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1161\/01.STR.0000014509.11540.66","article-title":"Blood pressure and clinical outcomes in the International Stroke Trial","volume":"33","author":"Leonardi-Bee","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib91","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1161\/01.STR.30.12.2598","article-title":"Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial","volume":"30","author":"Lewandowski","year":"1999","journal-title":"Stroke"},{"issue":"15","key":"10.1016\/j.pharmthera.2005.05.006_bib92","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1001\/jama.292.15.1862","article-title":"Long-term outcome after intravenous thrombolysis of basilar artery occlusion","volume":"292","author":"Lindsberg","year":"2004","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.pharmthera.2005.05.006_bib93","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/01.WCB.0000126236.54306.21","article-title":"Neuroprotection of ischemic brain by vascular endothelial growth factor is critically dependent on proper dosage and may be compromised by angiogenesis","volume":"24","author":"Manoonkitiwongsa","year":"2004","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib94","series-title":"The prevalence of disability among adults. Office of population censuses and surveys","article-title":"OPCS surveys of disability in Great Britain report 1","author":"Martin","year":"1988"},{"issue":"11","key":"10.1016\/j.pharmthera.2005.05.006_bib95","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1161\/01.STR.0000098003.50143.17","article-title":"Amphetamines for improving stroke recovery: a systematic cochrane review","volume":"34","author":"Martinsson","year":"2003","journal-title":"Stroke"},{"issue":"24","key":"10.1016\/j.pharmthera.2005.05.006_bib96","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1056\/NEJMoa011503","article-title":"Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both","volume":"345","author":"Mas","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib97","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM199607183350301","article-title":"Thrombolytic therapy with streptokinase in acute ischemic stroke","volume":"335","author":"MAST-E: The Multicenter Acute Stroke Trial-Europe Study Group","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib98","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S0140-6736(95)92049-8","article-title":"Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke","volume":"346","author":"MAST-I: The Multicentre Acute Stroke Trial-Italy Group","year":"1995","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pharmthera.2005.05.006_bib99","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1523\/JNEUROSCI.4485-03.2004","article-title":"Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia","volume":"24","author":"McCullough","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib100","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMoa011258","article-title":"A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke","volume":"345","author":"Mohr","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib101","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1161\/hs1201.99821","article-title":"Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: a case-control study","volume":"32","author":"Molina","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib102","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1212\/WNL.42.5.976","article-title":"Intravenous recombinant tissue plasminogen activator in acute carotid artery stroke","volume":"42","author":"Mori","year":"1992","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.pharmthera.2005.05.006_bib103","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001244","article-title":"Excitatory amino acid antagonists for acute stroke","author":"Muir","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.pharmthera.2005.05.006_bib104","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0092-8674(02)00862-0","article-title":"Regeneration of hippocampal pyramidal neurons after ischemic brain injury by recruitment of endogenous neural progenitors","volume":"110","author":"Nakatomi","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib105","doi-asserted-by":"crossref","first-page":"10954","DOI":"10.1073\/pnas.95.18.10954","article-title":"Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia","volume":"95","author":"Nakayama","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib106","first-page":"1581","article-title":"rt-PA Stroke Trial Tissue plasminogen activator for acute ischemic stroke","author":"National Institute of Neurological Disorders and Stroke (NINDS)","year":"1995","journal-title":"NEJM"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib107","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1161\/hs0302.104615","article-title":"Old microbleeds are a potential risk factor for cerebral bleeding after ischemic stroke: a gradient-echo T2*-weighted brain MRI study","volume":"33","author":"Nighoghossian","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib108","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1523\/JNEUROSCI.17-08-02746.1997","article-title":"Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage","volume":"17","author":"Nogawa","year":"1997","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib109","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJM199108153250701","article-title":"Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis","volume":"325","author":"North American Symptomatic Carotid Endarterectomy Trial Collaboration","year":"1991","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.pharmthera.2005.05.006_bib110","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1212\/01.WNL.0000092498.75010.57","article-title":"Detrimental effect of blood pressure reduction in the first 24 hours of acute stroke onset","volume":"61","author":"Oliveira-Filho","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib111","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/ana.1257","article-title":"Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke","volume":"50","author":"Pariente","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib112","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack","volume":"358","author":"PROGRESS Collaborative Group","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib113","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0140-6736(95)92836-7","article-title":"Cholesterol, diastolic blood pressure and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts","volume":"346","author":"Prospective Studies Collaboration","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib114","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.CIR.98.9.839","article-title":"Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels","volume":"98","author":"Ridker","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib115","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1161\/01.STR.0000015555.21285.DB","article-title":"Thrombolytic therapy within 3 to 6 hours after onset of ischemic stroke","volume":"33","author":"Ringleb","year":"2002","journal-title":"Stroke"},{"issue":"13","key":"10.1016\/j.pharmthera.2005.05.006_bib116","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archinte.154.13.1449","article-title":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials","volume":"154","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib117","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/bmj.313.7050.147","article-title":"Blood pressure and risk of stroke in patients with cerebrovascular disease","volume":"313","author":"Rodgers","year":"1996","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.pharmthera.2005.05.006_bib118","first-page":"12","article-title":"The effects of blood pressure lowering in cerebrovascular disease","volume":"2","author":"Rodgers","year":"1997","journal-title":"Neurol Rev Int"},{"issue":"3","key":"10.1016\/j.pharmthera.2005.05.006_bib119","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1179\/016164104225014076","article-title":"Transplantation for stroke","volume":"26","author":"Roitberg","year":"2004","journal-title":"Neurol Res"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib120","doi-asserted-by":"crossref","first-page":"303","DOI":"10.7326\/0003-4819-117-4-303","article-title":"Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients","volume":"11","author":"Rosove","year":"1992","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.pharmthera.2005.05.006_bib121","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.pharmthera.2005.05.006_bib122","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.20.8.983","article-title":"Determinants of early recurrence of cerebral infarction. The Stroke Data Bank","volume":"20","author":"Sacco","year":"1989","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib123","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1055\/s-0038-1657522","article-title":"Antiplatelet therapy with aspirin in acute ischaemic stroke","volume":"78","author":"Sandercock","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib124","series-title":"The cochrane library, issue 1","article-title":"Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack (Cochrane Review)","author":"Sandercock","year":"2004"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib125","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/archneur.61.7.1066","article-title":"Number needed to treat estimates incorporating effects over the entire range of clinical outcomes. Novel derivation method and application to thrombolytic therapy for acute stroke","volume":"61","author":"Saver","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib126","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1161\/01.STR.0000124458.98123.52","article-title":"Prehospital neuroprotective therapy for acute stroke: results of the field administration of stroke therapy magnesium (FAST-MAG) pilot trial","volume":"35","author":"Saver","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib127","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/01.STR.0000051504.10095.9C","article-title":"Imaging-based decision making in thrombolytic therapy for ischemic stroke: present status","volume":"34","author":"Schellinger","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib128","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"issue":"9459","key":"10.1016\/j.pharmthera.2005.05.006_bib129","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(05)17923-9","article-title":"Of rats and men: superwarfarin toxicity","volume":"365","author":"Sharma","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib130","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1001\/jama.283.18.2395","article-title":"Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial","volume":"282","author":"Sherman","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib131","unstructured":"SITS-MOST. (2005). Safe Implementation of Thrombolysis in Stroke Monitoring Study. Available at: http:\/\/www.acutestroke.org. Accessed February 2005."},{"issue":"2","key":"10.1016\/j.pharmthera.2005.05.006_bib132","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/01.WNL.0000130360.21618.D0","article-title":"Modulation of the renin\u2013angiotensin\u2013aldosterone system for the secondary prevention of stroke","volume":"63","author":"Sokol","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib133","first-page":"1308","article-title":"Intracranial balloon angioplasty of acute terminal internal carotid artery occlusions","volume":"23","author":"Song","year":"2002","journal-title":"Am J Neuroradiol"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib134","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial","volume":"362","author":"SPORTIF III Investigators","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib135","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(98)01401-9","article-title":"Prevalence of atrial fibrillation and eligibility for anticoagulants in the community","volume":"352","author":"Sudlow","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib136","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1161\/01.ATV.0000030360.72503.56","article-title":"Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol","volume":"22","author":"Sukhova","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib137","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/S0140-6736(99)05388-X","article-title":"Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Collaborators","volume":"353","author":"Taylor","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib138","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1161\/01.CIR.0000034508.55617.65","article-title":"ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol. A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness","volume":"106","author":"Taylor","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib139","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1161\/01.STR.28.12.2557","article-title":"Effect of antihypertensives treatment in patients having already suffered from stroke: gathering the evidence","volume":"28","author":"The INDIANA (Individual Data Analysis of Antihypertensive intervention trials) Project Collaborators","year":"1997","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib140","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/01.CIR.0000084501.48570.F6","article-title":"Randomized double-blind, placebo-controlled, international trial of the oral IIb\/IIIa antagonist lotrafiban in coronary and cerebrovascular disease","volume":"108","author":"Topol","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib141","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1212\/01.WNL.0000094325.95097.86","article-title":"Risk of recurrent stroke and recurrent dissection after cervical artery dissection","volume":"61","author":"Touze","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib142","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Effects of different blood-pressure lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials","volume":"362","author":"Turnbull","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib143","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1161\/01.STR.25.8.1547","article-title":"Shear-induced platelet aggregation in cerebral ischaemia","volume":"25","author":"Uchiyama","year":"1994","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.pharmthera.2005.05.006_bib144","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0196-0644(03)00609-7","article-title":"Association between course of blood pressure within the first 24 hours and functional recovery after acute ischemic stroke","volume":"42","author":"Vlcek","year":"2003","journal-title":"Ann Emerg Med"},{"issue":"7","key":"10.1016\/j.pharmthera.2005.05.006_bib145","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/01.STR.0000132196.49028.a4","article-title":"Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats","volume":"35","author":"Wang","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib146","first-page":"3","article-title":"Thrombolysis for acute ischaemic stroke (Cochrane Review)","author":"Wardlaw","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib147","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1161\/01.STR.29.7.1389","article-title":"Prognosis of patients with symptomatic vertebral or basilar artery stenosis","volume":"29","author":"WASID (The Warfarin-Aspirin Symptomatic Intracranial Disease Study)","year":"1998","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib148","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM199709043371007","article-title":"Low molecular-weight heparins","volume":"337","author":"Weitz","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib149","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/01.CIR.97.6.544","article-title":"Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors","volume":"97","author":"Weitz","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib150","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.jhh.1001683","article-title":"Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV","volume":"18","author":"Williams","year":"2004","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib151","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1001\/archneur.56.9.1087","article-title":"Dipyridamole plus aspirin in cerebrovascular disease","volume":"56","author":"Wilterdink","year":"1999","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.pharmthera.2005.05.006_bib152","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1291\/hypres.27.271","article-title":"Amlodipine and carvedilol prevent cytotoxicity in cortical neurons isolated from stroke-prone spontaneously hypertensive rats","volume":"27","author":"Yamagata","year":"2004","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2005.05.006_bib153","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1741-7015-2-4","article-title":"Rising statin use and effect on ischemic stroke outcome","volume":"2","author":"Yoon","year":"2004","journal-title":"BMC Med"},{"issue":"5\u20136","key":"10.1016\/j.pharmthera.2005.05.006_bib154","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0049-3848(03)00240-8","article-title":"Is there a hypercoagulable phase during initiation of antithrombotic therapy with oral anticoagulants in patients with atrial fibrillation?","volume":"109","author":"Zeuthen","year":"2003","journal-title":"Thromb Res"},{"issue":"25","key":"10.1016\/j.pharmthera.2005.05.006_bib155","doi-asserted-by":"crossref","first-page":"5810","DOI":"10.1523\/JNEUROSCI.1109-04.2004","article-title":"Stroke transiently increases subventricular zone cell division from asymmetric to symmetric and increases neuronal differentiation in the adult rat","volume":"24","author":"Zhang","year":"2004","journal-title":"J Neurosci"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725805001051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725805001051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T19:08:47Z","timestamp":1552936127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725805001051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":153,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["S0163725805001051"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2005.05.006","relation":{},"ISSN":["0163-7258"],"issn-type":[{"type":"print","value":"0163-7258"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}